- Published
- 2022-07-08
- Venue
- Nature Reviews Drug Discovery, vol. 21, no. 8, pp. 551
- Cited by
- 231
- Open access
- No free copy found
- DOI
- 10.1038/d41573-022-00120-3
- PubMed
- 35804044
Cite this paper
Formatted from the source metadata, not typed by hand. For a whole reference list, use the citation generator or ask your assistant through Find Research.
- APA 7
Ochoa, D., Karim, M. A., Ghoussaini, M., Hulcoop, D. G., McDonagh, E. M., & Dunham, I. (2022). Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. Nature Reviews Drug Discovery, 21(8), 551. https://doi.org/10.1038/d41573-022-00120-3
- MLA 9
Ochoa, David, et al. "Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs." Nature Reviews Drug Discovery, vol. 21, no. 8, 2022, pp. 551, https://doi.org/10.1038/d41573-022-00120-3.
- Chicago
Ochoa, David, Mohd Anisul Karim, Maya Ghoussaini, David G. Hulcoop, Ellen M. McDonagh, and Ian Dunham. "Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs." Nature Reviews Drug Discovery 21, no. 8 (2022): 551. https://doi.org/10.1038/d41573-022-00120-3.
- GOST
Ochoa D., Karim M. A., Ghoussaini M. [и др.] Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs // Nature Reviews Drug Discovery. — 2022. — Vol. 21, № 8. — P. 551. — URL: https://doi.org/10.1038/d41573-022-00120-3
- BibTeX
@article{ochoa2022human, title = {{Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs}}, author = {David Ochoa and Mohd Anisul Karim and Maya Ghoussaini and David G. Hulcoop and Ellen M. McDonagh and Ian Dunham}, journal = {Nature Reviews Drug Discovery}, year = {2022}, volume = {21}, number = {8}, pages = {551}, doi = {10.1038/d41573-022-00120-3}, url = {https://doi.org/10.1038/d41573-022-00120-3} }- RIS
TY - JOUR AU - Ochoa, David AU - Karim, Mohd Anisul AU - Ghoussaini, Maya AU - Hulcoop, David G. AU - McDonagh, Ellen M. AU - Dunham, Ian TI - Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs JO - Nature Reviews Drug Discovery VL - 21 IS - 8 SP - 551 PY - 2022 DA - 2022/07/08 DO - 10.1038/d41573-022-00120-3 UR - https://doi.org/10.1038/d41573-022-00120-3 ER -